Navigation Links
STERIS To Present at the UBS Global Life Sciences Conference on September 22, 2009
Date:9/10/2009

MENTOR, Ohio, Sept. 10 /PRNewswire-FirstCall/ -- STERIS Corporation (NYSE: STE) today announced that the Company will be presenting at the UBS Global Life Sciences Conference in New York on Tuesday, September 22, 2009. Michael J. Tokich, STERIS's chief financial officer, will begin the presentation at 12:30 p.m., Eastern time.

The presentation can be accessed live via webcast on STERIS Corporation's investor relations website at www.steris-ir.com. The presentation will be archived on the site through October 6, 2009.

About STERIS

The mission of STERIS Corporation is to provide a healthier today and safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products and services. The Company has approximately 5,000 dedicated employees around the world working together to supply a broad array of solutions by offering a combination of equipment, consumables and services to healthcare, pharmaceutical, industrial and government Customers. The Company is listed on the New York Stock Exchange under the symbol STE. For more information, visit www.steris.com.

Contact: Julie Winter, Director, Investor Relations at 440-392-7245.

This news release, and presentation referenced here, may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to the Company or its industry that are intended to qualify for the protections afforded "forward-looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this report, and may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "targets," "forecasts," "outlook," "potential," "confidence," "improve," "optimistic," "comfortable," and "seeks," or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, actions of regulatory agencies, and changes in government regulations or the application or interpretation thereof. Other risk factors are described in the Company's Form 10-K and other securities filings. Many of these important factors are outside STERIS's control. No assurances can be provided as to any outcome from litigation, regulatory action, administrative proceedings, government investigations, warning letters, cost reductions, business strategies, level of share repurchases or dividends, earnings and revenue trends, expense reduction or other future financial results. Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, (a) the potential for increased pressure on pricing that leads to erosion of profit margins, (b) the possibility that market demand will not develop for new technologies, products or applications, or the Company's business initiatives will take longer, cost more or produce lower benefits than anticipated, (c) the possibility that application of or compliance with laws, court rulings, regulations, regulatory actions, including without limitation previously disclosed FDA warning letters and government investigations, certifications or other requirements or standards may delay or prevent new product introductions, affect the production and marketing of existing products, or otherwise affect Company performance, results, or value, (d) the potential of international unrest or effects of fluctuations in currencies, tax assessments or rates, raw material costs, benefit or retirement plan costs, or other regulatory compliance costs, (e) the possibility of reduced demand, or reductions in the rate of growth in demand, for the Company's products and services, (f) the possibility that anticipated cost savings or other results may not be achieved, or that transition, labor, competition, timing, execution, regulatory, governmental, or other issues or risks associated with the matters described in this release, and the conference call referenced here, may adversely impact Company performance, results, or value, (g) the effect of the credit crisis on our ability, as well as the ability of our customers and suppliers, to adequately access the credit markets when needed, and (h) those risks described in our Annual Report on Form 10-K for the year ended March 31, 2009, filed with the SEC on May 30, 2009, under Item 1A, "Risk Factors."


'/>"/>
SOURCE STERIS Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. STERIS Corporation Announces Fiscal 2010 First Quarter Results
2. STERIS Corporation Announces Date of Fiscal 2010 First Quarter Earnings Release and Conference Call
3. Medical Device Sterilization Seminar Offered by STERIS Isomedix Services
4. STERIS Corporation Announces Quarterly Dividend Increase of 38%
5. STERIS Corporation Announces Date of Fiscal 2009 Fourth Quarter and Full Year Earnings Release and Conference Call
6. STERIS Corporation Announces Fiscal 2009 Third Quarter Results
7. STERIS Corporation Declares Regular Quarterly Dividend
8. STERIS Corporation Submits New Sterilization System To FDA and Announces Developments on SYSTEM 1 Warning Letter
9. STERIS Isomedix Services Offers Medical Device Sterilization Seminar
10. STERIS Corporation Postpones Analyst Day
11. STERIS Corporation Announces Webcast of Analyst Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Super-Sod will attend the Athens ... in Athens, Georgia. , A shift from Super-Sod’s simple Athens Home Show booth of ... the booth, grass seed plant manager Chris Roquemore constructed furniture from recycled pallet wood ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... BrightStar ... several sponsors of the Medical University of South Carolina (MUSC) Center on Aging’s ... Pleasant, SC. “MUSC’s Center on Aging is a tremendous resource in our community. We ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... for supply chain management (SCM) and spend management, today announced that Keppel Corporation ... time, and simplify expense tracking. , “We are excited to announce the ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... five new hospital-grade power extension cords that meet the most current standards. , ... 2012 edition of the National Fire Protection Association (NFPA) 101 – Life Safety ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... and problems directly related to surgery, treatment, therapy and management. Regular exercise in ... better qualities of life despite their diseases. On February 23, 2017, 1:00-2:00 p.m. ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... Research and Markets has announced the addition of ... Infrared, Mercury; Trend Indicator):Analysis By Region, By Country (2016-21)" report ... ... at a CAGR of 5.33% during 2016-2021 The strong ... with surging demand of digital thermometer. Apart from that, the downfall ...
(Date:2/22/2017)... 2017 Oncternal Therapeutics, Inc., a clinical-stage ... and common malignancies, today announced the closing of ... intends to use the proceeds to further clinical ... advance preclinical development of a new ROR1-targeted antibody-drug ... first-in-class anti-ROR1 monoclonal antibody being developed to treat ...
(Date:2/22/2017)... 22, 2017 Kineta, Inc., a biotechnology ... immune modulating therapies, today announced that KCP-400 (RgIA4), ... receptor (nAChR), demonstrates robust chronic pain relief and ... study also establishes the a9a10 nAChR as a ... pain. The findings were reported online in the ...
Breaking Medicine Technology: